CPRIT Bridging the Gap: Early Translational Research Awards

Limited Submission Funding Opportunity for Texas A&M University

CPRIT Bridging the Gap: Early Translational Research Awards
http://www.cprit.state.tx.us/images/uploads/rfa_r-12-etra-1.pdf

Cancer Prevention & Research Institute of Texas (CPRIT)

PI Eligibility and limit: 1
The Principal Investigator (PI) must have a doctoral degree, including M.D., Ph.D., D.D.S., D.M.D., Dr. P.H., D.O., D.V.M., or equivalent, and must reside in Texas during the time the research that is the subject of the grant is conducted.  A PI may submit only 1 application under this RFA during this funding cycle.

Institutional Limits
Texas A&M University, 4; all others, 2 each.

Institutional Eligibility
The applicant must be a Texas-based entity. Any not-for-profit institution that conducts research is eligible to apply for funding under this award mechanism.  Agrilife, TEES and Research Services is eligible to submit this proposal.

Summary
Areas of interest include translational preclinical studies that establish proof-of-concept. A detailed preclinical development plan that demonstrates the translation of the preclinical work to the eventual clinical studies will be required.

The current trend strongly favors programs with a strong proof-of-concept that can be undertaken at an acceptable level of risk. Increasingly, this is taken as a clear preclinical indication of a population subset or biomarker approach allowing selection of an enhanced patient population more likely to respond to the therapy.  Examples of fundable projects include those that incorporate the study of potential biomarkers of use for the clinic, such as biomarkers for selection of patients (e.g., tumors with mutations in EGFR, DDR2, BRAF) and/or biomarkers that can be utilized as pharmacodynamic end points (e.g., measurement of bone degradation products in preclinical animal studies and early clinical studies of treatment of bony metastases), tissue distribution, preliminary stability or other “drugability” criteria, or safety pharmacology studies conducted in compliance with ICH Guidelines and, thus, usable in a formal FDA regulatory submission.

Funding
Applicants may request a maximum of $1,000,000 in total costs over a period of 1 to 3 years.

Dates
July 22, 2011, 5:00 p.m.:
Deadline for an email of intent, including the names of the PI, title of internal proposal and a 1-3 sentence description of the project.

Send email of intent to limitedsubmissions@tamu.edu

July 25, 2011, 5:00 p.m.: Deadline to submit an internal proposal, including signatures of approval from your department head and college dean, to the Office of Research Development for review by the internal selection committee.

Send internal application to limitedsubmissions@tamu.edu

July 29, 2011: The Internal Selection Committee will notify PIs of the result of the internal competition.

November 22, 2011, 3:00 pm: Deadline for the full proposal.

Internal Selection Procedures
Texas A&M University has established a process to identify limited submission opportunities and internally select applications for Texas A&M submissions.